Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Delta 4-desaturase, sphingolipid 1 (DEGS1) is an integral membrane enzyme belonging to the membrane fatty acid desaturase family. It is responsible for introducing a double bond at the Delta4 position during sphingolipid biosynthesis, specifically converting D‑erythro‑sphinganine to D‑erythro‑sphingosine. This reaction is essential for generating bioactive sphingoid bases that function as important signaling molecules in eukaryotic cells. The enzyme contains three histidine-rich motifs characteristic of this protein family and localizes primarily to the endoplasmic reticulum. Mutations or dysregulation in DEGS1 have been linked to rare neurodegenerative disorders such as hypomyelinating leukodystrophies. Its activity can be inhibited by certain natural products including curcumin and Δ9-tetrahydrocannabinol.
Inhibition of DEGS1 enzymatic activity by small molecules such as curcumin and THC reduces the formation of desaturated sphingolipids, potentially altering cell signaling and lipid homeostasis.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Delta 4-desaturase, sphingolipid 1 (DEGS1).